Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 4Other neoplasm 2Classical hematology 2Plasma cell 1Dermatologic 1

Conditions

Melanoma 5Wilms Tumor 2Sarcoma 2Osteosarcoma 2Neoplasms 2Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hepatoblastoma 1Hematologic Diseases 1Gallbladder Neoplasms 1Esophageal Neoplasms 1

Interventions

Brentuximab Vedotin 2fludarabine phosphate 1Mycophenolic Acid 1Mesna 1Melphalan 1Filgrastim 1Cyclophosphamide 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Mesna × Dermatologic × Clear all
NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡